Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$17.78
0.352.01%
Pre-Market: 4:22 AM EDT
Comments
Loading...
IDEAYA Biosciences Analyst Ratings and Price Targets | NASDAQ:IDYA | Benzinga
IDEAYA Biosciences Inc has a consensus price target of $46.17 based on the ratings of 19 analysts. The high is $68 issued by Stifel on September 10, 2024. The low is $24 issued by Baird on November 18, 2022. The 3 most-recent analyst ratings were released by Stephens & Co., RBC Capital, and Wedbush on February 14, 2025, January 15, 2025, and December 17, 2024, respectively. With an average price target of $54.33 between Stephens & Co., RBC Capital, and Wedbush, there's an implied 205.59% upside for IDEAYA Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stephens & Co.
RBC Capital
Wedbush
Leerink Partners
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for IDEAYA Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/14/2025 | Buy Now | 181.21% | Stephens & Co. | Sudan Loganathan31% | $50 → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 01/15/2025 | Buy Now | 243.08% | RBC Capital | Gregory Renza48% | $61 → $61 | Reiterates | Outperform → Outperform | Get Alert |
| 01/13/2025 | Buy Now | — | Cantor Fitzgerald | Li Watsek41% | — | Reiterates | Overweight → Overweight | Get Alert |
| 12/17/2024 | Buy Now | — | Cantor Fitzgerald | Li Watsek41% | — | Reiterates | Overweight → Overweight | Get Alert |
| 12/17/2024 | Buy Now | 192.46% | Wedbush | Robert Driscoll44% | $52 → $52 | Reiterates | Outperform → Outperform | Get Alert |
| 11/18/2024 | Buy Now | 186.84% | Stephens & Co. | Sudan Loganathan31% | → $51 | Initiates | → Overweight | Get Alert |
| 11/05/2024 | Buy Now | 51.86% | Leerink Partners | Christopher Liu49% | $41 → $27 | Downgrade | Outperform → Market Perform | Get Alert |
| 10/29/2024 | Buy Now | 198.09% | Oppenheimer | Matthew Biegler37% | $53 → $53 | Reiterates | Outperform → Outperform | Get Alert |
| 10/24/2024 | Buy Now | 181.21% | UBS | David Dai26% | → $50 | Initiates | → Buy | Get Alert |
| 09/24/2024 | Buy Now | 192.46% | Wedbush | Robert Driscoll44% | $54 → $52 | Maintains | Outperform | Get Alert |
| 09/24/2024 | Buy Now | 243.08% | RBC Capital | Gregory Renza48% | $61 → $61 | Reiterates | Outperform → Outperform | Get Alert |
| 09/10/2024 | Buy Now | 282.45% | Stifel | Benjamin Burnett46% | $63 → $68 | Maintains | Buy | Get Alert |
| 08/27/2024 | Buy Now | 226.21% | Citigroup | Yigal Nochomovitz54% | $60 → $58 | Maintains | Buy | Get Alert |
| 08/08/2024 | Buy Now | 271.2% | JP Morgan | Anupam Rama60% | $69 → $66 | Maintains | Overweight | Get Alert |
| 08/07/2024 | Buy Now | 243.08% | RBC Capital | Gregory Renza48% | $61 → $61 | Reiterates | Outperform → Outperform | Get Alert |
| 08/07/2024 | Buy Now | 203.71% | Wedbush | Robert Driscoll44% | $54 → $54 | Reiterates | Outperform → Outperform | Get Alert |
| 08/07/2024 | Buy Now | 198.09% | Oppenheimer | Matthew Biegler37% | $60 → $53 | Maintains | Outperform | Get Alert |
| 07/12/2024 | Buy Now | 288.08% | JP Morgan | Anupam Rama60% | $65 → $69 | Maintains | Overweight | Get Alert |
| 07/11/2024 | Buy Now | 243.08% | RBC Capital | Gregory Renza48% | $53 → $61 | Maintains | Outperform | Get Alert |
| 07/09/2024 | Buy Now | 248.71% | BTIG | Justin Zelin40% | $55 → $62 | Maintains | Buy | Get Alert |
| 07/08/2024 | Buy Now | 254.33% | Stifel | Benjamin Burnett46% | $63 → $63 | Maintains | Buy | Get Alert |
| 07/08/2024 | Buy Now | 237.46% | Oppenheimer | Matthew Biegler37% | $53 → $60 | Maintains | Outperform | Get Alert |
| 07/08/2024 | Buy Now | 181.21% | Mizuho | Graig Suvannavejh54% | → $50 | Initiates | → Outperform | Get Alert |
| 06/04/2024 | Buy Now | 254.33% | Stifel | Benjamin Burnett46% | $55 → $63 | Maintains | Buy | Get Alert |
| 05/13/2024 | Buy Now | 158.72% | Goldman Sachs | Corinne Jenkins45% | $53 → $46 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | 192.46% | Wedbush | Robert Driscoll44% | $52 → $52 | Reiterates | Outperform → Outperform | Get Alert |
| 03/21/2024 | Buy Now | 237.46% | Citigroup | Yigal Nochomovitz54% | $40 → $60 | Maintains | Buy | Get Alert |
| 03/08/2024 | Buy Now | 209.34% | BTIG | Justin Zelin40% | → $55 | Initiates | → Buy | Get Alert |
| 02/23/2024 | Buy Now | 220.58% | JP Morgan | Anupam Rama60% | $51 → $57 | Maintains | Overweight | Get Alert |
| 02/21/2024 | Buy Now | 198.09% | RBC Capital | Gregory Renza48% | $43 → $53 | Maintains | Outperform | Get Alert |
| 01/26/2024 | Buy Now | 198.09% | Goldman Sachs | Corinne Jenkins45% | $36 → $53 | Maintains | Buy | Get Alert |
| 01/25/2024 | Buy Now | 198.09% | Goldman Sachs | Corinne Jenkins45% | $36 → $53 | Maintains | Buy | Get Alert |
| 01/10/2024 | Buy Now | 141.84% | RBC Capital | Gregory Renza48% | $36 → $43 | Maintains | Outperform | Get Alert |
| 12/06/2023 | Buy Now | 102.47% | RBC Capital | Gregory Renza48% | $36 → $36 | Reiterates | Outperform → Outperform | Get Alert |
| 11/30/2023 | Buy Now | 130.6% | JP Morgan | Anupam Rama60% | $35 → $41 | Maintains | Overweight | Get Alert |
| 11/13/2023 | Buy Now | 141.84% | Wedbush | Robert Driscoll44% | → $43 | Reiterates | Outperform → Outperform | Get Alert |
| 11/08/2023 | Buy Now | 147.47% | Guggenheim | Vanck Zhu75% | $48 → $44 | Maintains | Buy | Get Alert |
| 11/08/2023 | Buy Now | 141.84% | Wedbush | Robert Driscoll44% | → $43 | Reiterates | Outperform → Outperform | Get Alert |
| 10/24/2023 | Buy Now | 102.47% | RBC Capital | Gregory Renza48% | $32 → $36 | Maintains | Outperform | Get Alert |
| 10/11/2023 | Buy Now | 79.98% | RBC Capital | Gregory Renza48% | → $32 | Reiterates | Outperform → Outperform | Get Alert |
| 09/12/2023 | Buy Now | 141.84% | Wedbush | Robert Driscoll44% | $40 → $43 | Maintains | Outperform | Get Alert |
| 09/12/2023 | Buy Now | 108.1% | Goldman Sachs | Corinne Jenkins45% | $31 → $37 | Maintains | Buy | Get Alert |
| 08/17/2023 | Buy Now | 79.98% | JP Morgan | Anupam Rama60% | $28 → $32 | Maintains | Overweight | Get Alert |
| 08/11/2023 | Buy Now | 79.98% | RBC Capital | Gregory Renza48% | $30 → $32 | Maintains | Outperform | Get Alert |
| 08/11/2023 | Buy Now | 124.97% | Wedbush | Robert Driscoll44% | $35 → $40 | Maintains | Outperform | Get Alert |
| 08/11/2023 | Buy Now | 96.85% | Oppenheimer | Matthew Biegler37% | $30 → $35 | Maintains | Outperform | Get Alert |
| 08/08/2023 | Buy Now | 85.6% | SVB Leerink | Christopher Liu49% | → $33 | Initiates | → Outperform | Get Alert |
| 05/24/2023 | Buy Now | 79.98% | Goldman Sachs | Corinne Jenkins45% | → $32 | Initiates | → Buy | Get Alert |
| 04/24/2023 | Buy Now | 124.97% | Guggenheim | Vanck Zhu75% | $32 → $40 | Maintains | Buy | Get Alert |
| 04/24/2023 | Buy Now | 34.98% | Stifel | Benjamin Burnett46% | $18 → $24 | Upgrade | Hold → Buy | Get Alert |
| 03/23/2023 | Buy Now | 46.23% | Berenberg | Zhiqiang Shu21% | → $26 | Initiates | → Buy | Get Alert |
| 03/08/2023 | Buy Now | 79.98% | Guggenheim | Charles Zhu60% | → $32 | Reiterates | → Buy | Get Alert |
| 03/08/2023 | Buy Now | 40.61% | RBC Capital | Gregory Renza48% | → $25 | Reiterates | → Outperform | Get Alert |
| 02/28/2023 | Buy Now | 40.61% | RBC Capital | Gregory Renza48% | → $25 | Initiates | → Outperform | Get Alert |
| 12/28/2022 | Buy Now | 63.1% | Capital One | Zegbeh Jallah65% | → $29 | Initiates | → Overweight | Get Alert |
| 11/18/2022 | Buy Now | 34.98% | Baird | Joel Beatty69% | $18 → $24 | Maintains | Outperform | Get Alert |
| 10/27/2022 | Buy Now | 46.23% | Citigroup | Yigal Nochomovitz54% | → $26 | Initiates | → Buy | Get Alert |
| 09/13/2022 | Buy Now | 79.98% | Guggenheim | Charles Zhu60% | $20 → $32 | Maintains | Buy | Get Alert |
| 08/16/2022 | Buy Now | 1.24% | Baird | Joel Beatty69% | $26 → $18 | Maintains | Outperform | Get Alert |
| 08/16/2022 | Buy Now | 12.49% | Oppenheimer | Matthew Biegler37% | $25 → $20 | Maintains | Outperform | Get Alert |
| 08/15/2022 | Buy Now | -26.88% | Stifel | Benjamin Burnett46% | $16 → $13 | Downgrade | Buy → Hold | Get Alert |
FAQ
What is the target price for IDEAYA Biosciences (IDYA) stock?
The latest price target for IDEAYA Biosciences (NASDAQ:IDYA) was reported by Stephens & Co. on February 14, 2025. The analyst firm set a price target for $50.00 expecting IDYA to rise to within 12 months (a possible 181.21% upside). 26 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for IDEAYA Biosciences (IDYA)?
The latest analyst rating for IDEAYA Biosciences (NASDAQ:IDYA) was provided by Stephens & Co., and IDEAYA Biosciences reiterated their overweight rating.
When was the last upgrade for IDEAYA Biosciences (IDYA)?
The last upgrade for IDEAYA Biosciences Inc happened on April 24, 2023 when Stifel raised their price target to $24. Stifel previously had a hold for IDEAYA Biosciences Inc.
When was the last downgrade for IDEAYA Biosciences (IDYA)?
The last downgrade for IDEAYA Biosciences Inc happened on November 5, 2024 when Leerink Partners changed their price target from $41 to $27 for IDEAYA Biosciences Inc.
When is the next analyst rating going to be posted or updated for IDEAYA Biosciences (IDYA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IDEAYA Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IDEAYA Biosciences was filed on February 14, 2025 so you should expect the next rating to be made available sometime around February 14, 2026.
Is the Analyst Rating IDEAYA Biosciences (IDYA) correct?
While ratings are subjective and will change, the latest IDEAYA Biosciences (IDYA) rating was a reiterated with a price target of $50.00 to $50.00. The current price IDEAYA Biosciences (IDYA) is trading at is $17.78, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.